| ORIGINAL ARTICLE |
|
| Year : 2017 | Volume
: 20
| Issue : 9 | Page : 1122-1126 |
|
|
Occult metabolic bone disease in chronic pancreatitis
KVS Hari Kumar1, AK Sood2, M Manrai2
1 Department of Endocrinology, Army Hospital (R&R), Delhi, India
2 Department of Gastroenterology, Army Hospital (R&R), Delhi, India
Correspondence Address:
KVS Hari Kumar
Department of Endocrinology, Army Hospital (R&R), Delhi - 110 010
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/njcp.njcp_42_17
|
|
|
Background: Chronic pancreatitis (CP) leads to malabsorption and metabolic bone disease (MBD). Alcoholic CP (ACP) and tropical CP (TCP) are the two common types of CP. Objective: We investigated the presence of occult MBD in patients with CP and compared the same between ACP and TCP. Materials and Methods: In this cross-sectional, observational study, we included serial patients of CP in different stages and are grouped as ACP (Group 1; n = 67) and TCP (Group 2; n = 35). We determined serum calcium, phosphorus, alkaline phosphatase, 25-hydroxyvitamin D (25OHD), and intact parathyroid hormone (PTH) levels. Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry in the neck of the left femur. MBD was defined by the presence of either low bone mass (Z-score <−2) or osteomalacia. The results were analyzed using appropriate statistical methods. Results: The study participants (85 males; 17 females) had a mean age of 40.8 ± 12.6 years, CP duration of 3.7 ± 4.7 years, and Body Mass Index of 22.5 ± 3.2 kg/m2. A total of 37 (36%) patients had MBD (osteomalacia in 31 and low bone mass in 6). The frequency of MBD was same in the TCP (16/35) and ACP (21/65) groups (P = 0.1940). Elevated PTH (>70 pg/mL) was seen in 14 patients with 25OHD deficiency and low calcium (<8.5 mg/dL) in 29 patients. BMD did not show a significant correlation with the duration of CP. Conclusion: Occult MBD is seen in a third of patients with CP and is similar irrespective of the etiology. The disease is silent and mandates active screening in all susceptible individuals. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
